

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 10, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 10, 2019**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware                      001-33357                      65-0643773**  
**(State or other jurisdiction) (Commission File Number) (IRS Employer)**



Exchange Act. "

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Protalix BioTherapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders on January 10, 2019 (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares of the Company’s common stock, par value \$0.001 per share, authorized for issuance from 250,000,000 to 350,000,000. Set forth below are the number of votes cast for and against, and the number of abstentions, for the proposal.

Approval of an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of shares our common stock, par value \$0.001 per share, authorized for issuance from 250,000,000 to 350,000,000

For	Against	Abstain
74,755,268	14,044,511	373,156

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: January 10, 2019 By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Vice President and  
Chief Financial Officer